travoprost
Trade name: travatan
Approved
Mar 16, 2001
Travoprost, an isopropyl ester prodrug, is a synthetic prostaglandin F2 alpha analogue that is rapidly hydrolyzed by esterases in the cornea to its biologically active free acid. The travoporst free acid is potent and highly selective for the FP prostanoid receptor. Travoprost free acid is a selective FP prostanoid receptor agonist and is believed to reduce intraocular pressure by increasing the drainage of aqueous humor, which is done primarily through increased uveoscleral outflow and to a lesser extent, trabecular outflow facility. Travoprost ophthalmic solution is used for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension who are intolerant of other intraocular pressure lowering medications or insufficiently responsive (failed to achieve target IOP determined after multiple measurements over time) to another intraocular pressure lowering medication. Travoprost is known by the brand names of Travatan and Travatan Z, manufactured by Alcon. — NCATS
Clinical trial activity
133 trials · 49 clinical orgs · 15 marketing orgs
Earliest trial started Jan 1, 2000 (NCT00051181)
Timeline
2000s
2010s
- Aug 19, 2011
Par Pharmaceuticals — Marketing Organization
- Jan 1, 2013
- Mar 1, 2013
Strides Pharma Science — Marketing Organization
- Mar 1, 2013
Chartwell Pharmaceuticals — Marketing Organization
- Jul 10, 2015
Apotex — Marketing Organization
- Jul 7, 2017
Mylan — Marketing Organization
- Dec 20, 2019
Alembic — Marketing Organization
2020s
- Mar 19, 2021
Micro Labs Ltd India — Marketing Organization
- Dec 13, 2023
Glaukos Corporation — Marketing Organization
- May 3, 2024
Lupin — Marketing Organization
- Jul 12, 2024
Gland Pharma Ltd — Marketing Organization
- Sep 23, 2024
Somerset Pharmaceuticals — Marketing Organization
Indications
Approved for
Studied for
- Blood Pressure · Phase 4
- Corneal Diseases · Phase 2
- Dry Eye Syndromes · Phase 4
- Exfoliation Syndrome · Phase 3
- General Surgery · Phase 4
- Glaucoma, Angle-Closure · Phase 4
- Graves Ophthalmopathy · Phase 4
- Hyperemia · Phase 4
- Intraocular Pressure · Phase 4
- Lasers · Phase 4
- Lasers, Excimer · Phase 4
- Low Tension Glaucoma · Phase 4
- Macular Edema · Phase 4
- Pediatrics · Phase 3
- Pigmentation · Phase 4
- Uveitis, Anterior · Phase 4
- Vitiligo · Phase 4
Mechanism of action
- Prostanoid FP receptorAGONIST
PTGFR agonist
Approval history
- approvedPriority reviewMar 16, 2001
Chemistry & pharmacology
SMILES
CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)COC2=CC(=CC=C2)C(F)(F)F- Mol. weight
- 500.5477 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Topical
- Availability
- Prescription Only
Oral
No
Parenteral
No
Topical
Yes
Sources
- WikipediaTravoprost ↗
- NCATSWJ68R08KX9 ↗
- ChEMBLCHEMBL1200799 ↗
Also known as
- al-6221
- al-6221
- isopropyl (z)-7-((1r,2r,3r,5s)-3,5-dihydroxy-2-{(1e,3r)-3-hydroxy-4-[(alpha,alpha,alpha-trifluoro-m-tolyl)oxy]-1-butenyl}cyclopentyl)-5-heptenoate
- isopropyl (z)-7-((1r,2r,3r,5s)-3,5-dihydroxy-2-{(1e,3r)-3-hydroxy-4-[(alpha,alpha,alpha-trifluoro-m-tolyl)oxy]-1-butenyl}cyclopentyl)-5-heptenoate
- izba
- izba
- izba
- izba
- izba
- izba
- travaprost
- travatan
- travatan
- travatan
- travatan
- travatan
- travatanz
- travatan z
- travatan z
- travoprost
- travoprost
- travoprost
- travoprost
- travoprost
- travoprost
- travoprost
- travoprost
- travoprost
- travoprost
- travoprost / timolol
- travoprostum
- travoprostum
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07228221 | Phase 4 | Jan 5, 2026 | Glaukos Corporation, Thomas Jefferson University |
| NCT06848946 | Phase 4 | Jan 13, 2025 | Glaukos Corporation |
| NCT06152861 | Phase 2 | Nov 15, 2023 | Glaukos Corporation |
| NCT06066645 | Phase 3 | Sep 14, 2023 | Glaukos Corporation |
| NCT06061718 | Phase 3 | Sep 11, 2023 | Glaukos Corporation |
| NCT05335122 | Phase 2 | Mar 16, 2022 | Ocular Therapeutix, Inc. |
| NCT04962009 | N/A | Sep 8, 2021 | Mati Therapeutics Inc. |
| NCT06582732 | Phase 2 | Mar 10, 2021 | Glaukos Corporation |
| NCT04577027 | Phase 4 | Jan 1, 2021 | Assiut University |
| NCT04615403 | Phase 2 | Nov 30, 2020 | Glaukos Corporation |
| NCT04868175 | N/A | Oct 1, 2019 | The University of Hong Kong |
| NCT03965052 | Phase 1 | Apr 23, 2019 | Laboratorios Sophia S.A de C.V. |
| NCT03868124 | Phase 3 | Aug 2, 2018 | Glaukos Corporation |
| NCT04061044 | Phase 3 | Jul 10, 2018 | Ocular Therapeutix, Inc. |
| NCT03519386 | Phase 3 | May 31, 2018 | Glaukos Corporation |
| NCT02914509 | Phase 3 | Sep 1, 2016 | Ocular Therapeutix, Inc. |
| NCT02796560 | Phase 4 | Jul 1, 2016 | University of Sherbrooke |
| NCT02730871 | Phase 4 | Jun 17, 2016 | Alcon |
| NCT02754596 | Phase 2 | Mar 1, 2016 | Glaukos Corporation |
| NCT02419508 | Phase 4 | Aug 7, 2015 | Alcon |
Organizations
Research & Development (49)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Alcon | For profit | 73 | 68 | 5 | 2000 |
| Glaukos Corporation | For profit | 13 | 12 | 3 | 2011 |
| Allergan | For profit | 6 | 6 | 1 | 2006 |
| Ocular Therapeutix, Inc. | For profit | 5 | 5 | 3 | 2013 |
| Aristotle University of Thessaloniki | Academic/Hospital | 4 | 4 | 2 | 2006 |
| Pfizer | For profit | 3 | 1 | 1 | 2002 |
| S.V. Malayan Eye Center | Academic/Hospital | 3 | 0 | 1 | 2011 |
| Aerie Pharmaceuticals | For profit | 2 | 2 | 1 | 2011 |
| Innovative Medical Research of South Florida, Inc | For profit | 2 | 2 | 1 | 2006 |
| Singapore National Eye Centre | Academic/Hospital | 2 | 1 | 1 | 2007 |
| Thomas Jefferson University | Academic/Hospital | 2 | 2 | 1 | 2008 |
| University of Pittsburgh | Academic/Hospital | 2 | 0 | 1 | 2006 |
| University of Sao Paulo | Academic/Hospital | 2 | 2 | 1 | 2005 |
| University of Sherbrooke | Academic/Hospital | 2 | 2 | 2 | 2009 |
| Afyon Kocatepe University | Academic/Hospital | 1 | 1 | 1 | 2014 |
| Alan L. Robin, M.D. | Academic/Hospital | 1 | 0 | 1 | 2005 |
| Arlington eye Associates | Academic/Hospital | 1 | 0 | 1 | 2008 |
| Assiut University | Academic/Hospital | 1 | 1 | 1 | 2021 |
| Cairo University | Academic/Hospital | 1 | 1 | 1 | 2011 |
| Envisia Therapeutics | For profit | 1 | 1 | 1 | 2015 |
Marketing (21)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Alcon | For profit | NDA | Mar 16, 2001 |
| Alembic | For profit | MKTG | Dec 20, 2019 |
| Alembic | For profit | SYN | Dec 20, 2019 |
| Apotex | For profit | MKTG | Jul 10, 2015 |
| Apotex | For profit | SYN | Jul 10, 2015 |
| Chartwell Pharmaceuticals | For profit | MKTG | Mar 1, 2013 |
| Gland Pharma Ltd | For profit | MKTG | Jul 12, 2024 |
| Gland Pharma Ltd | For profit | SYN | Jul 12, 2024 |
| Glaukos Corporation | For profit | MKTG | Dec 13, 2023 |
| Lupin | For profit | MKTG | May 3, 2024 |
| Lupin | For profit | SYN | May 3, 2024 |
| Micro Labs Ltd India | For profit | MKTG | Mar 19, 2021 |
| Mylan | For profit | MKTG | Jul 7, 2017 |
| Mylan | For profit | SYN | Jul 7, 2017 |
| Nestle | For profit | NDA2 | Mar 16, 2001 |
| Novartis | For profit | NDA2 | Sep 21, 2006 |
| Novartis | For profit | MKTG | Sep 21, 2006 |
| Par Pharmaceuticals | For profit | MKTG | Aug 19, 2011 |
| Sandoz | For profit | MKTG | Sep 21, 2006 |
| Somerset Pharmaceuticals | For profit | MKTG | Sep 23, 2024 |
| Strides Pharma Science | For profit | MKTG | Mar 1, 2013 |